Department of Hepatology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shimen, Jingan District, Shanghai, China.
Medicine (Baltimore). 2021 Apr 2;100(13):e25105. doi: 10.1097/MD.0000000000025105.
To evaluate the effect of astragaloside IV for hepatic fibrosis.The multiple databases like Pubmed, Embase, Cochrane databases, and China National Knowledge database were used to search for the relevant studies, and full-text articles involved in the evaluation on effect of astragaloside IV for hepatic fibrosis. Review Manager 5.2 was adopted to estimate the effects of the results among selected articles. Forest plots, sensitivity analysis and bias analysis for the articles included were also conducted.Finally, 7 eligible studies were eventually satisfied the included criteria. Alanine aminotransferase (ALT) in model was higher than astragaloside group (mean difference [MD] = -58.01, 95% confidential interval (CI) [-93.97, -22.05], P = .002; I2 = 99%). The meta-analysis suggested that aspartate aminotransferase (AST) in model group was more than that in astragaloside group (MD = -39.94, 95% CI [-129.38, 49.50], P = .38; I2 = 100%). Model group had higher α - smooth muscle actin (α-SMA) than astragaloside group (MD was -1.13, P of heterogeneity <.0001, I2 = 94%, Z = 5.18, P of over effect <.0001). Transforming growth factor β (TGF-β) in model group was higher than that in astragaloside group (MD was -0.55, P of heterogeneity <.00001, I2 = 97%, Z = 2.54, P of over effect = .01). Limited publication bias was observed in this study.Astragaloside IV is a potential clinical drug for the treatment of liver fibrosis considering liver function and hepatic fibrosis related protein factor in experimental rats are improved.
评价黄芪甲苷抗肝纤维化的作用。
计算机检索 Pubmed、Embase、Cochrane 数据库和中国知网等多个数据库，搜集有关黄芪甲苷抗肝纤维化的随机对照试验，检索时限均从建库至 2018 年 3 月。由 2 位研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后，采用 RevMan 5.2 软件进行 Meta 分析。
最终纳入 7 项研究，共 606 只大鼠。Meta 分析结果显示：模型组大鼠丙氨酸氨基转移酶（ALT）高于黄芪甲苷组[MD=-58.01，95%CI（-93.97，-22.05），P=0.002；I2=99%]；模型组大鼠天门冬氨酸氨基转移酶（AST）高于黄芪甲苷组[MD=-39.94，95%CI（-129.38，49.50），P=0.38；I2=100%]；模型组大鼠α-平滑肌肌动蛋白（α-SMA）高于黄芪甲苷组[MD=-1.13，P 异质性<0.0001，I2=94%，Z=5.18，P 检验=0.0002]；模型组大鼠转化生长因子β（TGF-β）高于黄芪甲苷组[MD=-0.55，P 异质性<0.00001，I2=97%，Z=2.54，P 检验=0.01]。
黄芪甲苷可能是一种潜在的抗肝纤维化的临床药物，可改善实验性肝纤维化大鼠肝功能及肝纤维化相关蛋白因子。
